Be a Smart Investor
Monday, January 22, 2018
Sanofi digs deep to buy US hemophilia specialist Bioverativ for $11.6 billion
The French drugmaker is nearing a deal to acquire biotechnology company Bioverativ for $105 a share.
from Mergers and Acquisitions http://ift.tt/2DweOCr
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment